TSC1 and lymphangioleiomyomatosis: However, as many LAM patient tumors do not exhibit TSC mutations especially in S-LAM cases [139], biochemical signaling due to activation of the mTOR pathway does not solely account for tumorigenesis in LAM [138,140,141].